Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.55 USD | +4.60% | +47.15% | -69.62% |
May. 16 | CVRx, Inc. Announces Executive Appointments | CI |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 3.53 times the sales for the current fiscal year, the company turns out to be overvalued.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-69.62% | 197M | C- | ||
-24.49% | 7.29B | C+ | ||
+5.94% | 6.75B | C- | ||
+18.57% | 5.5B | D+ | ||
-18.64% | 4.75B | B | ||
+18.17% | 4.1B | - | ||
-22.29% | 3.93B | B- | ||
-26.73% | 2.7B | C | ||
+43.40% | 2.31B | C- | ||
+1.86% | 2.06B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVRX Stock
- Ratings CVRx, Inc.